
OptimizeRx Corp (OPRX) Stock Forecast & Price Target
OptimizeRx Corp (OPRX) Analyst Ratings
Bulls say
OptimizeRx Corp has demonstrated substantial financial growth, with contracted revenue increasing by 30% year-over-year and a notable revenue beat contributing to enhanced margins and earnings per share (EPS) performance. The company’s guidance for 2025 includes revenue growth expectations in the high teens to low twenties, reflecting strong visibility of over 85% for total revenue and at least 70% for the second half of 2025. Furthermore, projected EBITDA guidance surpasses consensus estimates, highlighting OptimizeRx's solid operational foundation and capability to maintain a revenue run-rate of approximately $150 million while keeping expenses stable.
Bears say
OptimizeRx Corp operates within the competitive healthcare technology market, yet it has recently experienced declining revenue growth, which raises concerns about its ability to maintain market share. Additionally, rising operational costs, coupled with increased research and development expenditures, may negatively impact profitability margins moving forward. Furthermore, the company faces regulatory challenges and potential disruptions in healthcare policy that could hinder its ability to execute its strategic initiatives effectively.
This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.
OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction
Start investing in OptimizeRx Corp (OPRX)
Order type
Buy in
Order amount
Est. shares
0 shares